The other issue that was being discussed here is the whole after-market question. You have a drug that's put on the market, now it's being prescribed to more people, and all of a sudden we're finding...you know, the Vioxx story, or others. The only way, I would suggest, to follow that in any realistic manner in real time would be to have electronic monitoring. So all of a sudden you'd start flagging this issue. It's coming up, and it has happened a dozen times, instead of 12,000 or 50,000 times.
That's all.